NCT02643303 2022-12-02A Study of Tremelimumab and IV Durvalumab Plus Poly-ICLC in Subjects With Biopsy-accessible CancersLudwig Institute for Cancer ResearchPhase 1/2 Completed58 enrolled 24 charts
NCT00052715 2018-07-18Poly-ICLCSidney Kimmel Comprehensive Cancer Center at Johns HopkinsPhase 2 Terminated31 enrolled 8 charts